Steris Healthcare Redefines Indian Pharma with Affordable Access and People-First Values.
New Delhi [India], June 24: In an industry undergoing rapid transformation—driven by innovation, regulatory evolution, and rising patient expectations—Steris Healthcare Pvt. Ltd. has emerged as a force of quiet consistency and impactful intent. Since its inception in 2018, the company has worked toward a singular mission: making quality healthcare affordable and accessible across India. What began as a focused vision is now a fast-growing pan-India pharmaceutical brand, recognized for its therapeutic depth, operational scale, and purpose-driven ethos. With its headquarters in Mumbai and strong operational bases in Jaipur and Bengaluru, Steris Healthcare is building one of the most reliable distribution-backed pharma footprints in the country—expanding reach, deepening category presence, and bringing care to the doorstep of millions.
Delivering Accessible Quality Across Therapeutic Segments
At the heart of Steris Healthcare’s operations lies a robust and ever-evolving product portfolio—spanning over 750 branded formulations across more than 17 therapeutic categories. These include cardiology, neurology, urology, gastroenterology, dermatology, diabetes, respiratory care, pediatrics, and general medicine.
Steris Healthcare’s products are developed in collaboration with WHO-GMP and ISO-certified manufacturing facilities, ensuring global quality compliance while maintaining affordability. The portfolio covers essential and high-demand molecules like Glimepiride + Metformin, Pregabalin-Duloxetine, and Ambrisentan, alongside innovative formats like effervescent tablets, pediatric suspensions, and advanced fixed-dose combinations. Each formulation reflects the company’s commitment to efficacy, safety, and doctor-driven demand.
The Vision Behind the Brand
Leading Steris Healthcare is Jeevan Kasara, a first-generation entrepreneur whose values of accessibility, transparency, and execution form the core DNA of the company. His conviction—that no Indian patient should be denied essential medicines due to cost barriers or supply challenges—has shaped the brand’s people-first philosophy and